Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer. Transl. 2020;9:1333–42. https://doi.org/10.21037/tlcr-20-377. Article CAS Google ...
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in young children and elderly people. Although the virus was isolated in 1955, an effective RSV vaccine has not been developed, and the only licensed intervention is passive immunoprophylaxis of high-risk infant...
We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development. This is a preview of subscription content, access via your institution ...
The widespread use of eGFR in particular is an important step forward, but it necessarily represents a simplification. This review will present an overview over the potential and limitations of the most common endogenous GFR markers and estimations of GFR presently used in clinical practice. Access ...
Estimated GFR (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration eGFR creatinine-cystatin C (eGFRcreat-cys) equation. The effect of increasing HDL-C serum levels was assessed using Cox proportional hazard models. In participants with normal kidney function (eGFR>90 ml/...
Once dose escalation is performed in clinical studies, the suboptimal balance of clinical dose/efficacy/toxicity may lead to clinical development failures. For instance, analysis of U.S. Food and Drug Administration (FDA)-approved EGFR inhibitors (gefinitib, lapatinib, erlotinib, and vandetanib) ...
least one outpatient eGFR measurements (excluding implausible values and measurements while patient on dialysis or after transplant) between January 1, 2007 and December 31, 2009, and these patients should have at least one yearly glucose measurement within one year before the first eGFR measurement....
In addition, in EGFR/ALK-altered NSCLC, there was no difference in survival between patients with tumor PD-L1 < 1% vs. ≥ 1% [6]. Therefore, PD-L1 is not always reliable as a biomarker of immune efficacy in patients with advanced NSCLC. ICIs can also be used as adjuvant or ...
TP53is a tumor suppressor gene involved in multiple cellular processes that coordinate DNA damage response [1]. SomaticTP53pathogenic variants (PVs) occur in most tumor types, and when present in the germline, they cause an autosomal dominant cancer susceptibility condition called Li-Fraumeni syndrome...
This allowed us to group together receptors with an equal number of pYs (that is, unphosphorylated EGFR (R0), 1pY-EGFR (R1), 2pY-EGFR (R2) and so on) regardless of the specific identity of the pY (Fig. 2c, lower panel). This simplification is justified by the observation that ...